Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT06911203 is recruiting with primary completion estimated Jan 2026; no results posted. Positive Phase 2 obesity data reported at ADA 2025 is from separate placebo-controlled study (CTR20233198), not this Tirzepatide comparator trial.
Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed75% confidenceGrok 4.20 (xAI)
Will the results be positive?
NCT06911203 (vs Tirzepatide, estimated primary completion Jan 2026) is recruiting with no results posted. Positive Phase 2 obesity data (744-P/ADA 2025: ~11-20% placebo-adjusted weight loss, well-tolerated) refers to a separate placebo-controlled Chinese trial (CTR20233198, ~24 weeks), not this head-to-head study. Sources do not address this exact trial's readout.
Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:23 PM
ClinicalTrialsclinicaltrials.gov
NCT06911203 | A Study of BGM0504 in Participants With Obesity
Phase 2, randomized open-label, multicenter vs Tirzepatide in adults with obesity without diabetes. Primary: change in body weight at Week 26. Status: Recruiting. Primary completion: 2026-01-11. No results posted.
Web Searchdiabetesjournals.orgJun 13, 2025, 12:00 AM
744-P: Efficacy and Safety of BGM0504 in Chinese Patients with Obesity—A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
Placebo-controlled Phase 2 (CTR20233198). LSM % weight change vs placebo: -10.77% to -19.78% at week 24. Demonstrates significant potential for weight management in overweight/obese non-diabetic individuals. Well tolerated.
Web Searchbiospace.comJun 24, 2025, 12:00 AM
BrightGene Presents Positive Phase 2 Data for Dual GLP-1R/GIPR Agonist for Weight Management and Type 2 Diabetes
Separate Phase 2 obesity study (placebo-controlled, 120 Chinese adults) showed significant weight loss and metabolic benefits. Positive framing for that trial; does not reference NCT06911203 or Tirzepatide comparator.
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:33 PM
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific public efficacy readout was found for NCT06911203. The exact Phase 2 obesity head-to-head vs tirzepatide still appears to be ongoing/recruiting, while BrightGene’s cited positive Phase 2 obesity data came from a different placebo-controlled study, not this exact trial.
Found Apr 3, 2026, 4:01 PMReviewed Apr 3, 2026, 4:48 PM
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public trial-specific readout was found for NCT06911203. The registry still shows the study as recruiting, and recent coverage describes the obesity head-to-head vs tirzepatide as ongoing rather than reported. That is insufficient to call this exact Phase 2 trial positive or negative.
Found Apr 1, 2026, 6:33 PMReviewed Apr 1, 2026, 6:36 PM